by Introduction to Circulating Cell-Free Tumor DNA
Circulating cell-free tumor DNA, also known as liquid biopsy, is DNA that is shed from dying cancer cells and circulates in the bloodstream. This circulating cell-free tumor DNA can provide important information about a patient’s cancer without requiring an invasive tissue biopsy. As tumor cells undergo cell death, fragments of tumor DNA are released into the bloodstream in small pieces known as circulating tumor DNA, or ctDNA. By analyzing a simple blood sample, important details about the cancer’s genetic profile, mutations, and response to treatments can be revealed through liquid biopsy tests.
Uses of ctDNA in Cancer Detection and Diagnosis
One of the major uses of Circulating Cell-Free Tumor DNA analysis is in cancer screening and early detection. Even in very early stage cancers before symptoms appear, tumor DNA can be detected in the bloodstream. Liquid biopsies provide a noninvasive alternative to tissue biopsies for monitoring disease recurrence or progression. They allow repeated sampling over time to track changes in the cancer’s genomic profile during and after therapy. Tracking ctDNA levels can help determine treatment effectiveness and identify potential relapse earlier than conventional imaging methods. Liquid biopsies are also being used to help diagnose cancer when a tissue biopsy cannot be obtained or guides which part of the body to biopsy.
Genomic Profiling Through ctDNA Analysis
Advanced liquid biopsy tests can analyze the Circulating Cell-Free Tumor DNA present in a blood sample to develop a comprehensive genetic profile of the patient’s tumor. These “liquid biopsies” provide an up-to-date snapshot of the genomic changes driving the cancer at any given time. Liquid profiling matches or exceeds the diagnostic capabilities of traditional tumor biopsies. It provides information on tumor mutational burden, microsatellite instability status, and detection of gene fusions and structural variations that are difficult to capture from tissue. This genomic intelligence gleaned from blood facilitates personalized treatment decisions and monitoring of therapy response in real-time.
Tracking Tumor Evolution and Identifying Resistance Mutations
One of the most significant clinical applications of ctDNA analysis is tracking how a tumor evolves and changes over time, both during and after administration of therapies. As cancer progresses or recurs, new mutations can arise that help the tumor evade the effects of drugs. Liquid biopsies allow clinicians to monitor for emerging “resistance mutations” and adjust treatments accordingly before the tumor begins to clinically relapse. ctDNA monitoring provides a powerful method for prompt identification of new targetable genomic alterations driving therapy failure. It enables timely changes to treatment regimens or enrollment in alternative clinical trials before the tumor regrows.
Helping Guide Immunotherapy Treatment Decisions
Immunotherapies like checkpoint inhibitors have revolutionized cancer treatment, but not all patients respond and resistance still develops. Liquid biopsies offer potential insights into a tumor’s immunogenic profile and help predict likely responsiveness to different immunotherapy regimens. Analysis of ctDNA may reveal tumor mutation burden, defects in DNA repair pathways like mismatch repair status, and expression of genes in tumor-infiltrating immune cells associated with response or resistance. Technologies are being developed to profile ctDNA for neoantigens recognized by the immune system as well as monitor emergence of resistance over time. Ultimately, ctDNA could facilitate personalized immunotherapy treatment planning and management of immunotherapies.
Challenges and Future Directions
While liquid biopsies represent an important advance, several challenges still must be addressed before their widespread clinical utility. Key among these is enhancing the sensitivity of ctDNA assays to detect disease at earlier stages and monitor responses to therapies that may only achieve partial or slow tumor reduction. Improving techniques to analyze small amounts of ctDNA present in blood is an active area of research. Standardization of testing methods and validation of results is also still needed across different clinical laboratories.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
